Loading...

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

Kai M Beeh,1 Dave Singh,2 Lilla Di Scala,3 Anton Drollmann31insaf Respiratory Research Institute, Wiesbaden, Germany; 2University Of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UK; 3Novartis Pharma AG, Basel, SwitzerlandIntroduction: Exercise limitatio...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Beeh KM, Singh D, Di Scala L, Drollmann A
Format: Artigo
Sprog:Inglês
Udgivet: Dove Medical Press 2012-07-01
Serier:International Journal of COPD
Online adgang:http://www.dovepress.com/once-daily-nva237-improves-exercise-tolerance-from-the-first-dose-in-p-a10558
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!